Up to 10% of all cancers are caused by inherited genetic mutations, but traditional screening approaches may miss more than 30% of eligible individuals.1,2 Myriad supports your health system goals with a robust, fully supported hereditary cancer risk assessment program that is designed to help you systematically identify, evaluate, and manage your at-risk patients, without adding complexity to your workflow or unnecessary burden to your staff. Medical management changes for the 53% of patients who qualify after MyRisk® testing3 may include important services such as enhanced imaging, specialist consultations, cancer screenings, and other risk reduction interventions that deliver improved outcomes and service-line utilization.
Executive BriefThe Unmet Opportunity in Hereditary Cancer Risk AssessmentRead now
ENHANCE CLINICAL EFFICACY
Identify more high-risk patients with pre-appointment digital screening and genetic testing during regularly scheduled appointments.
Offer on demand, no cost personalized education to help patients see the value in testing at the point of care.
The MyRisk® test accurately identifies high-risk patients that may be eligible for risk-reduction services such as: specialist consults, enhanced imaging, cancer screening, and prophylactic surgeries.
Infographic7 ways a hereditary cancer risk assessment program can identify more women for precision careRead now
VideoClinicians on Programmatic Hereditary Cancer Risk AssessmentWatch
Myriad provides beginning to end program support to help health systems like yours develop program workflows, provide ongoing staff training, educate patients before and after the test, integrate screening and ordering within your EMR, and streamline patient payment details.
Pre-visit screener in patient portalDigital screening with MyGeneHistory® based on medical society guidelines
Pre-test genetic educationPatient education materials are provided along with access to a board-certified genetic counselor
Simple MyRisk® test orderingOnline portal and RIS/EMR integration
AffordabilityMost eligible patients pay $0 out of pocket4, and financial assistance may be available for those that qualify
Actionable resultsEasy to use MyRisk® Management Tool and personalized 5-year and lifetime breast cancer RiskScore® for eligible patients
Post-test genetic consultsBoard-certified genetic counselors available M-F for individualized results support for patients and providers
Care management plan developmentClear guideline-based management recommendations to help with circle of care referrals
Streamline CLINICAL WORKFLOWS
Work with Myriad to implement a scalable hereditary cancer risk assessment program that identifies and manages high-risk patients and their close relatives across your system. With our EMR integrated digital tools, expert support, and proven implementation success, you can deliver more efficient, guideline-based care, while improving patient health outcomes and operational performance.5
ArticlesModernizing Genetic Counseling in Women’s Health Programs: Enhancing Clinical Workflows While Reducing Provider BurdenRead now
The Clinical Impact of Myriad’s Hereditary Cancer Genetic Testing and Prenatal ScreeningRead now
Together, we can implement a program that works in your health system — and supports your commitment to the best care.
By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.
Contact Information
case study
A multi-state health system’s hereditary cancer risk assessment program began with one clinician recognizing an opportunity to improve patients’ lives and the quality of care at her clinic. It became the framework for identifying and treating the women in their care who are at high-risk for hereditary cancer. Read how they did it.
“Affecting communities at the population health level can make lasting changes for generations to come. Moving away from a one-size-fits-all approach to cancer risk assessment and management improves quality of care and patient satisfaction.”
An OB/GYN at a multi-state health system
patients screened
eligible for genetic testing
tests reported
eligible for breast MRI (TCv8)
pathogenic mutations found
medical procedures selected for 6,369 patients
Health systems need to reduce the cost of healthcare without sacrificing quality. A programmatic approach to women’s hereditary cancer risk assessment can help.
spent on breast cancer care in the first two years following early-stage diagnosis6
vs.
spent on breast cancer care in first two years following late-stage diagnosis6
Expanding access, improving outcomes, and enhancing utilization.
According to a review of public data, 36% of Americans have at least one first-degree relative with cancer. Yet, a 2022 Myriad survey revealed that 30% of women don’t know whether their family has a history of cancer.
Genetic tests aren’t all the same. Learn why you need to consider accuracy, scientific rigor, and service offerings when deciding on which tests to use.
Genetic testing isn’t just about the results. Risk assessment, education, and counseling are also required. Learn how to identify testing labs that align with your value-based care goals.
View all